Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed breast cancer that metastasized to the brain, meeting all of the following criteria:~  * Must have ≥ 1 inoperable brain metastases, meeting 1 of the following criteria:~    * Progressive or recurrent disease after prior whole-brain or stereotactic radiotherapy~   * Ineligible for OR unwilling to be treated with radiotherapy~ * At least 1 unidimensionally measurable brain metastasis by enhanced MRI within the past 21 days~ * No progression or development of central nervous system (CNS) metastasis during prior treatment with capecitabine, fluorouracil, interferon alfa, or interferon beta~* Systemic (i.e., outside the CNS system) cancer must be stable~  * No progressive disease (e.g., liver, lymphangitic, or lung metastases)~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Male or female~Menopausal status~* Not specified~Performance status~* Karnofsky 70-100%~Life expectancy~* More than 12 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 mg/dL~* No history of idiopathic thrombocytopenic purpura~* No known uncontrolled coagulopathy~* No increased risk for anemia (e.g., thalassemia or spherocytosis)~* No medically problematic anemia~Hepatic~* aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) ≤ 2.5 times upper limit of normal (ULN) (5 times ULN for patients with concurrent liver metastases )~* Bilirubin ≤ 1.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN for patients with concurrent liver metastases; 10 times ULN for patients with concurrent bone metastases)~Renal~* Creatinine ≤ 1.5 times ULN OR~* Creatinine clearance ≥ 30 mL/min~Cardiovascular~* No congestive heart failure~* No symptomatic coronary artery disease~* No medically uncontrolled arrhythmia~* No other clinically significant cardiac disease~* No myocardial infarction within the past 12 months~Gastrointestinal~* No history of inflammatory bowel disease~* Must have intact upper gastrointestinal tract~* Able to swallow tablets~* No malabsorption syndrome~* No history of gastrointestinal bleeding~Immunologic~* No prior unanticipated severe reaction to fluoropyrimidine therapy, interferon, pegylated interferon, or a pegylated moiety~* No known sensitivity to fluorouracil~* No serious uncontrolled infection~* No history of immunologically mediated disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after completion of study treatment~* No known dihydropyrimidine dehydrogenase deficiency~* No history of depression characterized by a suicide attempt~* No history of hospitalization for psychiatric disease~* No history of other severe psychiatric disease~* No prior disability as a result of psychiatric disease~* No history of clinically significant psychiatric disability that would preclude study compliance~* No other malignancy within the past 5 years except cured nonmelanoma skin cancer or treated carcinoma in situ of the cervix~* No uncontrolled thyroid dysfunction (e.g., thyroid-stimulating hormone not in normal range)~* No evidence of severe retinopathy (e.g., Cytomegalovirus (CMV) retinitis or macular degeneration)~* No clinically relevant ophthalmologic disorders due to diabetes or hypertension~* No other serious uncontrolled medical conditions that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* At least 3 months since prior interferon alfa or interferon beta~Chemotherapy~* See Disease Characteristics~* At least 3 months since prior capecitabine or fluorouracil~Endocrine therapy~* Concurrent hormonal agents (e.g., tamoxifen, raloxifene, or anastrazole) for breast cancer allowed~Radiotherapy~* See Disease Characteristics~Surgery~* More than 4 weeks since prior major surgery and recovered~Other~* More than 4 weeks since prior participation in another investigational drug study~* At least 4 weeks since prior and no concurrent brivudine or sorivudine~* No concurrent cimetidine~* No other concurrent investigational or commercial agents or therapies for this malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine + PEG-interferon alfa-2a (Type: EXPERIMENTAL): Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues